HGS/GSK's Benlysta Gets Advisory Panel Backing For Lupus Labeling That Reflects Trials' Limitations
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Advisory Committee says belimumab efficacy is not shown for full spectrum of the disease, so the biologic should go to market with appropriate caveats.
You may also be interested in...
GSK Builds Autoimmune R&D With Immutep Deal
Immutep's antibody against recently activated T-lymphocytes could have potential in the treatment of autoimmune diseases.
GSK Builds Autoimmune R&D With Immutep Deal
Immutep's antibody against recently activated T-lymphocytes could have potential in the treatment of autoimmune diseases.
GSK's "Biotech-In-A-Pharma" R&D Model Makes Progress
Since the mid-2000s, GlaxoSmithKline has been working to rejuvenate its R&D organization, which it believed wasn't sufficiently productive. Industry watchers are gauging progress closely, particularly as the cornerstone of its new approach, the division of GSK's drug discovery operations into nearly 40 specialized and idiosyncratic Drug Performance Units, or DPUs, approaches milestone deadlines in 2011, and as the rest of the industry also struggles with R&D productivity.